ImmuPharma 주식 주식분석 | 주식가격 | 뉴스 | IMM.L | GB0033711010 | A0BMC4

날짜	ImmuPharma 주식 가격
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined
	0.02 undefined

날짜	ImmuPharma 매출	ImmuPharma EBIT	ImmuPharma 이익
2024e	99,474 undefined	0 undefined	0 undefined
2023	0 undefined	-3.06 백만 undefined	-2.92 백만 undefined
2022	0 undefined	-3.03 백만 undefined	-3.81 백만 undefined
2021	118,350 undefined	-5.16 백만 undefined	-8.17 백만 undefined
2020	126,670 undefined	-5.59 백만 undefined	-6.86 백만 undefined
2019	77,930 undefined	-6.28 백만 undefined	-6.12 백만 undefined
2018	81,280 undefined	-8.08 백만 undefined	-7.21 백만 undefined
2017	150,460 undefined	-7.23 백만 undefined	-6.22 백만 undefined
2016	164,780 undefined	-6.59 백만 undefined	-5.32 백만 undefined
2015	76,410 undefined	-4.56 백만 undefined	-3.9 백만 undefined
2014	184,820 undefined	-3.42 백만 undefined	-2.87 백만 undefined
2013	0 undefined	-4.23 백만 undefined	-3.69 백만 undefined
2012	0 undefined	-4.18 백만 undefined	-3.84 백만 undefined
2011	20,000 undefined	-3.84 백만 undefined	-3.36 백만 undefined
2010	30,000 undefined	-4.18 백만 undefined	-1.98 백만 undefined
2009	22.05 백만 undefined	9.04 백만 undefined	8.1 백만 undefined
2008	60,000 undefined	-4.58 백만 undefined	4.68 백만 undefined
2007	60,000 undefined	-3.53 백만 undefined	-3.08 백만 undefined
2006	50,000 undefined	-1.4 백만 undefined	-1.29 백만 undefined
2005	30,000 undefined	-1.53 백만 undefined	-2.48 백만 undefined

	매출	EBIT	이익
2005	30,000 GBP	-1.53 백만 GBP	-2.48 백만 GBP
2006	50,000 GBP	-1.4 백만 GBP	-1.29 백만 GBP
2007	60,000 GBP	-3.53 백만 GBP	-3.08 백만 GBP
2008	60,000 GBP	-4.58 백만 GBP	4.68 백만 GBP
2009	22.05 백만 GBP	9.04 백만 GBP	8.1 백만 GBP
2010	30,000 GBP	-4.18 백만 GBP	-1.98 백만 GBP
2011	20,000 GBP	-3.84 백만 GBP	-3.36 백만 GBP
2012	0 GBP	-4.18 백만 GBP	-3.84 백만 GBP
2013	0 GBP	-4.23 백만 GBP	-3.69 백만 GBP
2014	184,820 GBP	-3.42 백만 GBP	-2.87 백만 GBP
2015	76,410 GBP	-4.56 백만 GBP	-3.9 백만 GBP
2016	164,780 GBP	-6.59 백만 GBP	-5.32 백만 GBP
2017	150,460 GBP	-7.23 백만 GBP	-6.22 백만 GBP
2018	81,280 GBP	-8.08 백만 GBP	-7.21 백만 GBP
2019	77,930 GBP	-6.28 백만 GBP	-6.12 백만 GBP
2020	126,670 GBP	-5.59 백만 GBP	-6.86 백만 GBP
2021	118,350 GBP	-5.16 백만 GBP	-8.17 백만 GBP
2022	0 GBP	-3.03 백만 GBP	-3.81 백만 GBP
2023	0 GBP	-3.06 백만 GBP	-2.92 백만 GBP
2024e	99,474 GBP	0 GBP	0 GBP

2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e
0	0	0	0	22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	77.27	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-2	-1	-3	4	8	-1	-3	-3	-3	-2	-3	-5	-6	-7	-6	-6	-8	-3	-2	0
-	-50.00	200.00	-233.33	100.00	-112.50	200.00	-	-	-33.33	50.00	66.67	20.00	16.67	-14.29	-	33.33	-62.50	-33.33	-
59.66	68.39	72.78	81.84	81.61	81.17	81.53	81.53	81.66	83.6	88.62	117.34	130.9	138.84	153.45	200.18	251.16	302.91	362	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

2.69	6.46	2.95	12.46	22.53	15.59	12.16	8.89	5.4	5.42	0.83	1.88	2.73	4.91	1.36	5.86	1.65	0.67	0.21
140	0	0	0	0	20	0	10	0	0	0	0	0	0	0	0	0	166.32	0
0	0	0	0	1.35	1.13	1.29	0.82	1.08	0.7	1.02	0	0	0	0	0	0	1.18	0.69
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.02	0.02	0.02	0.02	0.01	0.03	0.03	0.04	0.03	0.02	0.56	2.84	0.65	0.15	1.51	1.08	0.56	0.33	0.45
2.85	6.48	2.97	12.48	23.89	16.77	13.48	9.76	6.51	6.15	2.41	4.72	3.37	5.07	2.87	6.95	2.21	2.34	1.34
10	10	10	10	10	80	130	110	100	366.36	280.13	231.9	161.4	164.66	206.74	411.61	353	389.72	102.08
0	0	0	0	0	0	0	0	0	0	0	0	0	2	0.69	2.42	1.42	0.69	0.64
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.48	1.13	1.18	0
770	750	760	810	750	700	670	630	600	560.54	522.46	511.09	482.27	483.04	478.96	484.04	477.55	473.89	447.57
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	843.15	174.49	405.49	82.56	184.78
0.78	0.76	0.77	0.82	0.76	0.78	0.8	0.74	0.7	0.93	0.8	0.74	0.64	2.65	2.22	3.97	3.78	2.82	1.38
3.63	7.24	3.74	13.3	24.65	17.55	14.28	10.5	7.21	7.07	3.21	5.46	4.02	7.71	5.09	10.92	5.99	5.15	2.72

6.81	7.28	7.28	7.75	8.11	8.15	9.68	8.15	9.89	8.86	10.57	14.24	15.53	18.29	23.06	25.02	28.5	28.98	29.81
1.61	3.56	3.56	5.49	7.3	7.45	7.45	7.45	7.76	10.49	10.49	15.68	18.73	27.32	27.19	27.24	27.24	28.79	29.32
-5.92	-4.95	-7.79	-2	2.67	0.37	-3.2	-7.18	-10.67	-13.65	-17.44	-22.76	-28.99	-36.19	-43.63	-41.33	-49.98	-53.98	-56.81
0	0	0	0	0	0	-1.42	0	-1.58	0	-1.93	-1.61	-1.7	-1.79	-1.35	-1.28	-1.34	-1.27	-1.26
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2.5	5.89	3.05	11.24	18.08	15.97	12.51	8.42	5.4	5.71	1.69	5.55	3.57	7.62	5.27	9.65	4.41	2.52	1.06
0.26	0.12	0.14	0.37	3.81	0.39	0.47	0.29	0.43	0.39	0.64	0.6	0.75	0.72	0.33	0.42	1.16	1.07	0.78
0.53	0.62	0.3	0.74	1.49	0.25	0.22	0.48	0.19	0.16	0.44	0.19	0.18	0.19	0.18	0.2	0.43	0.38	0.89
50	110	90	250	790	130	110	30	60	23.47	0	15.05	57.52	0	0	0	0	0	0
0	0	0	0	0	0	0	30	0	0.89	1.72	0.85	0.58	0.51	0	641.84	0.7	0.11	0
280	190	170	30	30	30	140	220	350	416.96	161.35	142.26	141.81	97.83	26.78	0	0	0	0
1.12	1.04	0.7	1.39	6.12	0.8	0.94	1.05	1.03	0.99	1.24	0.94	1.13	1.01	0.53	1.26	1.58	1.45	1.67
0	0.4	0.35	0.78	0.43	0.77	0.83	1.04	0.77	0.38	0.28	0.22	0.12	0.02	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	195.99	0	0	0	0	0	0
0	0.4	0.35	0.78	0.43	0.77	0.83	1.04	0.77	0.38	0.28	0.22	0.31	0.02	0	0	0	0	0
1.12	1.44	1.05	2.17	6.55	1.57	1.77	2.09	1.8	1.37	1.52	1.16	1.44	1.03	0.53	1.26	1.58	1.45	1.67
3.62	7.33	4.1	13.41	24.63	17.54	14.28	10.51	7.2	7.07	3.21	6.71	5.02	8.66	5.8	10.92	6	3.97	2.72

2005	null	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
-1	-1	-1	-3	-4	9	-4	-3	-4	-4	-3	-4	-6	-7	-8	-6	-5	-6	-3
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	2	-4	0	0	0	0	0	0	2	1	0	0	1	0
0	0	0	0	0	0	1	0	0	0	0	0	0	0	2	1	1	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	-1	0	0	0	0	0
0	0	-1	-3	-3	11	-6	-3	-3	-3	-2	-4	-6	-4	-4	-4	-3	-4	-2
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	-2	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	-1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,000	0	0
2	2	4	0	2	0	0	0	0	0	3	0	9	4	10	2	8	3	2
2	2	4	0	12	0	0	0	0	0	2	0	7	5	9	0	8	0	1
0	0	0	0	9	0	0	0	0	0	0	0	-1	1	0	-2	0	-2	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2	2	3	-3	9	10	-6	-3	-3	-3	0	-4	1	0	2	-3	4	-4	0
-1.23	0	-1.25	-3.79	-3.58	11.96	-6.93	-3.44	-3.27	-3.91	-2.84	-4.17	-6.49	-4.45	-4.82	-4.33	-3.69	-4.88	-2.45
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

ImmuPharma 브루토마진	ImmuPharma 이익 마진	ImmuPharma EBIT-마진	ImmuPharma 이익 마진
2024e	99.7 %	0 %	0 %
2023	99.7 %	0 %	0 %
2022	99.7 %	0 %	0 %
2021	99.7 %	-4,359.85 %	-6,906.56 %
2020	100.26 %	-4,412.59 %	-5,415.59 %
2019	99.7 %	-8,060.62 %	-7,857.81 %
2018	99.7 %	-9,941.17 %	-8,866.33 %
2017	99.7 %	-4,807.95 %	-4,136.12 %
2016	99.7 %	-3,998.77 %	-3,230.99 %
2015	99.7 %	-5,971.88 %	-5,100.77 %
2014	99.7 %	-1,853.1 %	-1,553.66 %
2013	99.7 %	0 %	0 %
2012	99.7 %	0 %	0 %
2011	99.7 %	-19,200 %	-16,800 %
2010	100 %	-13,933.33 %	-6,600 %
2009	81.18 %	41 %	36.73 %
2008	100 %	-7,633.33 %	7,800 %
2007	99.7 %	-5,883.33 %	-5,133.33 %
2006	99.7 %	-2,800 %	-2,580 %
2005	99.7 %	-5,100 %	-8,266.67 %

	브루토마진	EBIT-마진	이익 마진
2005	99.7 %	-5,100 %	-8,266.67 %
2006	99.7 %	-2,800 %	-2,580 %
2007	99.7 %	-5,883.33 %	-5,133.33 %
2008	100 %	-7,633.33 %	7,800 %
2009	81.18 %	41 %	36.73 %
2010	100 %	-13,933.33 %	-6,600 %
2011	99.7 %	-19,200 %	-16,800 %
2012	99.7 %	0 %	0 %
2013	99.7 %	0 %	0 %
2014	99.7 %	-1,853.1 %	-1,553.66 %
2015	99.7 %	-5,971.88 %	-5,100.77 %
2016	99.7 %	-3,998.77 %	-3,230.99 %
2017	99.7 %	-4,807.95 %	-4,136.12 %
2018	99.7 %	-9,941.17 %	-8,866.33 %
2019	99.7 %	-8,060.62 %	-7,857.81 %
2020	100.26 %	-4,412.59 %	-5,415.59 %
2021	99.7 %	-4,359.85 %	-6,906.56 %
2022	99.7 %	0 %	0 %
2023	99.7 %	0 %	0 %
2024e	99.7 %	0 %	0 %

날짜	ImmuPharma 주당 매출	ImmuPharma EBIT 당 주식	ImmuPharma 주당 이익
2024e	0 undefined	0 undefined	0 undefined
2023	0 undefined	-0.01 undefined	-0.01 undefined
2022	0 undefined	-0.01 undefined	-0.01 undefined
2021	0 undefined	-0.02 undefined	-0.03 undefined
2020	0 undefined	-0.03 undefined	-0.03 undefined
2019	0 undefined	-0.04 undefined	-0.04 undefined
2018	0 undefined	-0.06 undefined	-0.05 undefined
2017	0 undefined	-0.06 undefined	-0.05 undefined
2016	0 undefined	-0.06 undefined	-0.05 undefined
2015	0 undefined	-0.05 undefined	-0.04 undefined
2014	0 undefined	-0.04 undefined	-0.03 undefined
2013	0 undefined	-0.05 undefined	-0.05 undefined
2012	0 undefined	-0.05 undefined	-0.05 undefined
2011	0 undefined	-0.05 undefined	-0.04 undefined
2010	0 undefined	-0.05 undefined	-0.02 undefined
2009	0.27 undefined	0.11 undefined	0.1 undefined
2008	0 undefined	-0.06 undefined	0.06 undefined
2007	0 undefined	-0.05 undefined	-0.04 undefined
2006	0 undefined	-0.02 undefined	-0.02 undefined
2005	0 undefined	-0.03 undefined	-0.04 undefined

	주당 매출	EBIT 당 주식	주당 이익
2005	0 GBP	-0.03 GBP	-0.04 GBP
2006	0 GBP	-0.02 GBP	-0.02 GBP
2007	0 GBP	-0.05 GBP	-0.04 GBP
2008	0 GBP	-0.06 GBP	0.06 GBP
2009	0.27 GBP	0.11 GBP	0.1 GBP
2010	0 GBP	-0.05 GBP	-0.02 GBP
2011	0 GBP	-0.05 GBP	-0.04 GBP
2012	0 GBP	-0.05 GBP	-0.05 GBP
2013	0 GBP	-0.05 GBP	-0.05 GBP
2014	0 GBP	-0.04 GBP	-0.03 GBP
2015	0 GBP	-0.05 GBP	-0.04 GBP
2016	0 GBP	-0.06 GBP	-0.05 GBP
2017	0 GBP	-0.06 GBP	-0.05 GBP
2018	0 GBP	-0.06 GBP	-0.05 GBP
2019	0 GBP	-0.04 GBP	-0.04 GBP
2020	0 GBP	-0.03 GBP	-0.03 GBP
2021	0 GBP	-0.02 GBP	-0.03 GBP
2022	0 GBP	-0.01 GBP	-0.01 GBP
2023	0 GBP	-0.01 GBP	-0.01 GBP
2024e	0 GBP	0 GBP	0 GBP

	주식 수량
2005	59.66 백만 Aktien
2006	68.39 백만 Aktien
2007	72.78 백만 Aktien
2008	81.84 백만 Aktien
2009	81.61 백만 Aktien
2010	81.17 백만 Aktien
2011	81.53 백만 Aktien
2012	81.53 백만 Aktien
2013	81.66 백만 Aktien
2014	83.6 백만 Aktien
2015	88.62 백만 Aktien
2016	117.34 백만 Aktien
2017	130.9 백만 Aktien
2018	138.84 백만 Aktien
2019	153.45 백만 Aktien
2020	200.18 백만 Aktien
2021	251.16 백만 Aktien
2022	302.91 백만 Aktien
2023	362 백만 Aktien
2024e	362 백만 Aktien

%-지분	이름	주식	변경
9.99441 %	Lanstead Investors Pty Ltd	41,620,407	-12,491,451
5.28291 %	LUCA & Associates AG	22,000,000	0
5.12069 %	Chelverton Asset Management Ltd.	21,324,433	-1,175,567
2.61963 %	Alora Pharmaceuticals LLC	10,909,091	0
2.10074 %	Smith (Gary)	8,748,263	-1,475,228
2.08303 %	Parker (Philip)	8,674,500	7,320,500
2.03182 %	Elfatyany (Sameh)	8,461,267	0
1.46388 %	Lee (K)	6,096,126	1,751,289
1.28339 %	Zimmer (Robert Henri)	5,344,514	0
1.08364 %	Skinner (James)	4,512,684	1,651,639
0.81996 %	Freeman (Simon)	3,414,618	1,042,259
0.69279 %	Christie (Malcolm Andrew Bain)	2,885,043	1,080,640
0.60033 %	VP Bank AG	2,500,000	0
0.59441 %	Edgoose (M)	2,475,336	1,617,979
0.57210 %	Freeman (Olivia)	2,382,426	875,857
0.53466 %	Close Brothers Asset Management	2,226,531	-11,254
0.52576 %	DePass (Donovan)	2,189,445	816,397
0.46770 %	Gibson (Jeffrey Edward)	1,947,670	900,000
0.44842 %	Jeffs (John Benedict)	1,867,396	-584,046
0.38261 %	Freeman (Dillian)	1,593,314	170,714
0.38036 %	Baderoon (Lisa)	1,583,963	0
0.36020 %	Kerr (Andrew James)	1,500,000	100,000
0.36020 %	Taylor (Stephen)	1,500,000	300,000
0.35743 %	Mc-Carthy (Timothy Paul)	1,488,462	0
0.35527 %	Smith (Peter Edward)	1,479,477	426,830
0.30689 %	Hetherington (Jane)	1,278,022	236,839
0.27626 %	Ward (John)	1,150,439	0
0.27424 %	Booth (R)	1,142,017	300,169
0.27367 %	Javierre (J)	1,139,675	16,556
0.26555 %	Hawley (Renos)	1,105,851	0
0.26415 %	Ward (Robert Glendenning)	1,100,000	1,100,000
0.26050 %	Cheung (Tatyan)	1,084,812	91,271
0.25377 %	Buckton (Gavin)	1,056,795	836,732
0.24013 %	Demyttenaere (Jane)	1,000,000	-500,000
0.24013 %	Demyttenaere (Jacques David Wolfgang)	1,000,000	-1,650,000
0.23629 %	Robinson (Oliver)	983,980	112,701
0.23401 %	Stasiak (Mariusz)	974,500	186,500
0.23346 %	Leicester (Clive)	972,210	481,486
0.22835 %	Flute (Sheila)	950,945	500,000
0.22243 %	Commerzbank AG	926,291	103,000
0.22135 %	Welburn (Simon)	921,773	789,452
0.21993 %	Mr M & Mrs Z Jaffer	915,870	0
0.21776 %	Hall (Gerrard)	906,819	906,819
0.21372 %	Moore (David Robert John)	890,000	0
0.20938 %	Cherry (Amanda)	871,922	0
0.20051 %	Prudhoe (Kenneth)	835,000	415,000
0.19490 %	Pagden (Michael Ashley)	811,633	253,000
0.19138 %	Kodavali (Kalyan)	796,980	0
0.18610 %	Airey (Peter David)	775,000	0
0.18358 %	Iwaniec (A)	764,508	406,730
0.18010 %	Oates (Karen A)	750,000	300,000
0.18010 %	Briddon (Nigel)	750,000	330,000
0.18010 %	Morra (Dino)	750,000	0
0.17833 %	Hickman (Gillian Mary)	742,633	234,000
0.16225 %	Merricks (Andrew)	675,662	0
0.15897 %	UBS Fund Management (Switzerland) AG	662,000	-1,250,000
0.15397 %	Maybury (Amel)	641,197	0
0.15038 %	Morris (Barry)	626,218	112,028
0.14912 %	Smith (Raymond)	621,000	621,000
0.14408 %	Wollenberg (John Richard)	600,000	-25,000
0.14408 %	Jacobs (Laurence Anthony)	600,000	150,000
0.14354 %	Hussain (Zubeda)	597,736	0
0.13729 %	Guichard (Gilles Francois Roger)	571,721	0
0.13463 %	Rebaudengo (Dario)	560,649	0
0.13207 %	Joseph (A)	550,000	-200,000
0.12868 %	Flute (David George)	535,870	0
0.12607 %	Franklin (Timothy Gary)	525,000	0
0.12505 %	Mohammed (Burhanuddin)	520,744	165,941
0.12415 %	Shahid (M)	517,000	0
0.12295 %	Campbell (R)	512,000	0
0.12127 %	Kanani (J J)	505,000	-385,000
0.12075 %	Vallance (Michael)	502,854	0
0.12063 %	Carpenter (Howard Frederick)	502,352	43,791
0.12007 %	Foster (M)	500,000	0
0.12007 %	Wyatt (J)	500,000	100,000
0.12007 %	Cowley (Seumus)	500,000	0
0.12007 %	Kirwan (Thomas Anthony)	500,000	0
0.12007 %	Claridge (Patrick Timothy)	500,000	-500,000
0.11860 %	Downes (Brendan)	493,900	0
0.11809 %	Hussain (Ibrar)	491,785	491,785
0.11766 %	Thomas (Odile Allison)	490,000	271,184
0.11426 %	Graham (John)	475,831	150,060
0.11288 %	FinTech Group AG	470,059	-189,910
0.11192 %	Potts (Michael)	466,080	0
0.11098 %	Day (S)	462,151	462,151
0.10915 %	Reeve (Tracey)	454,523	454,523
0.10806 %	Mc-Lellan (Richard Martin Stuart)	450,000	0
0.10708 %	Emanuel (Stephen)	445,909	0
0.10606 %	Barclay (P)	441,687	0
0.10602 %	Fallaize (Michael)	441,490	0
0.10447 %	Martin (Paul Richard)	435,033	0
0.10400 %	O'Rorke (Vivienne)	433,100	0
0.10343 %	Archbold (Richard)	430,713	430,713
0.10302 %	Salt (N)	429,000	0
0.10176 %	Isiklar (O)	423,771	0
0.10153 %	Hall (Andrew Derrick)	422,813	0
0.10062 %	O'brien (P)	419,029	0
0.09845 %	Smith (Daniel Matthew)	410,000	0
0.09845 %	Crawford (D)	410,000	210,000
0.09756 %	Crausay (Norman William)	406,257	60,975

What values and corporate philosophy does ImmuPharma represent?

ImmuPharma PLC represents a values-driven corporate philosophy focused on innovation, scientific excellence, and delivering groundbreaking solutions to patients. The company is committed to enhancing human health through its cutting-edge research and development in the field of immunotherapy. ImmuPharma PLC places a strong emphasis on collaboration, fostering strategic partnerships with leading institutions and experts in the industry. With a steadfast commitment to patient well-being, ImmuPharma PLC strives to bring groundbreaking treatments to market, revolutionizing healthcare and improving quality of life.

In which countries and regions is ImmuPharma primarily present?

ImmuPharma PLC is primarily present in various countries and regions worldwide. The company has a global presence, with key markets and operations in Europe, including the United Kingdom, France, and Switzerland. ImmuPharma also extends its reach to other areas, such as Asia, North America, and South America. Through strategic partnerships and collaborations, ImmuPharma aims to expand its market presence and ensure accessibility of its innovative healthcare solutions to a diverse range of patients and healthcare professionals internationally.

What significant milestones has the company ImmuPharma achieved?

ImmuPharma PLC, a leading pharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed a Phase III clinical trial for its drug candidate, LupuzorTM, for the treatment of systemic lupus erythematosus (SLE). The trial showed promising results, demonstrating the drug's potential to address this debilitating autoimmune disease. Furthermore, ImmuPharma PLC secured a global licensing agreement with Avion Pharmaceuticals for the commercialization of LupuzorTM in the United States. This partnership ensures widespread access to this potentially life-changing treatment for SLE patients. ImmuPharma PLC's unwavering commitment to scientific innovation and partnership development has propelled it towards these remarkable achievements.

What is the history and background of the company ImmuPharma?

ImmuPharma PLC is a pharmaceutical company with a rich history and background. Founded in 1999, the company is focused on the development and commercialization of innovative therapeutics. ImmuPharma PLC has a diverse portfolio of drug candidates with a particular emphasis on autoimmune diseases and cancer. With extensive research and development capabilities, the company has made significant strides in advancing its drug candidates, including Lupuzor™ for lupus and Nucant for oncology. ImmuPharma PLC's commitment to scientific excellence and dedication to improving patient outcomes has positioned it as a leading player in the pharmaceutical industry.

Who are the main competitors of ImmuPharma in the market?

The main competitors of ImmuPharma PLC in the market include companies like Roche Holding AG, AstraZeneca PLC, Novartis AG, and GlaxoSmithKline PLC. These pharmaceutical companies operate in similar therapeutic areas and have developed competing drugs or treatments targeting the same diseases or medical conditions as ImmuPharma.

In which industries is ImmuPharma primarily active?

ImmuPharma PLC is primarily active in the pharmaceutical industry.

What is the business model of ImmuPharma?

The business model of ImmuPharma PLC is focused on developing and commercializing innovative drugs to treat serious medical conditions. The company's primary area of expertise lies in the field of autoimmune diseases and immune system disorders. ImmuPharma PLC aims to identify and advance biological compounds with the potential for improving patient outcomes and addressing unmet medical needs. By conducting research, clinical trials, and seeking regulatory approvals, ImmuPharma PLC strives to bring safe and effective therapeutic options to market, ultimately enhancing the quality of life for patients.

ImmuPharma 2024의 P/E 비율은 얼마입니까?

ImmuPharma의 P/E 비율은 0입니다.

ImmuPharma 2024의 KUV는 얼마입니까?

ImmuPharma의 P/S 비율은 60.05입니다.

ImmuPharma의 AlleAktien 품질 점수는 얼마인가요?

ImmuPharma에 대한 AlleAktien 품질 점수는 2/10입니다.

ImmuPharma 2024의 매출은 얼마인가요?

예상되는 ImmuPharma 매출은 99,474 GBP입니다.

ImmuPharma 2024의 이익은 얼마인가요?

ImmuPharma의 현재 이익을 계산할 수 없습니다.

ImmuPharma은 무엇을 하나요?

ImmuPharma PLC is a global biopharmaceutical company focused on developing therapeutics for the treatment of autoimmune diseases and cancer. It is headquartered in London, with subsidiaries in France and the USA. The company's business model is based on the identification, development, and commercialization of drugs made from peptides and proteins. It specializes in platform technologies that simplify the discovery and characterization of peptides and proteins. The company operates in multiple therapeutic areas, including the treatment of autoimmune diseases like lupus and multiple sclerosis. It has developed a drug called Lupuzor, currently in Phase III clinical trials and plans to market it in the USA and Europe once approved by regulatory authorities. In addition, ImmuPharma PLC is focused on cancer research and has developed a peptide called IPP-204106 that targets the CXCR4 receptor, which plays an important role in many types of cancer. The company is working on testing this peptide in clinical trials with patients who have advanced cancer. ImmuPharma PLC has also developed a platform technology called Ureka, which is specifically designed for the treatment of pain and inflammation. The company is currently working on several projects that utilize this technology, including peptides for the treatment of arthritis pain and chronic cough. In addition to developing its own products, ImmuPharma PLC collaborates with other companies to leverage their platform technologies and clinical expertise for the development of new treatments. It has partnerships with major pharmaceutical companies such as AstraZeneca and Ipsen to jointly develop new drugs. ImmuPharma PLC is listed on the London Stock Exchange and has a strong financial foundation. It has successfully completed multiple funding rounds and has a diversified investor base, including large institutional investors and private individuals. In summary, ImmuPharma PLC's business model is based on the development of innovative therapeutics for autoimmune diseases and cancer. The company specializes in platform technologies for the identification and characterization of peptides and proteins. It operates in multiple therapeutic areas and collaborates closely with other companies to develop new drugs. With its experience, expertise, and financial stability, ImmuPharma PLC is well positioned to continue its success.

ImmuPharma 배당금은 얼마입니까?

ImmuPharma은(는) 연간 번의 배당을 통해 0 GBP의 배당금을 지급합니다.

ImmuPharma이 얼마나 자주 배당을 지급하나요?

ImmuPharma의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

ImmuPharma ISIN이 무엇입니까?

ImmuPharma의 ISIN은 GB0033711010입니다.

ImmuPharma WKN은 무엇인가요?

ImmuPharma의 WKN은 A0BMC4입니다.

ImmuPharma 티커는 무엇인가요?

ImmuPharma의 티커는 IMM.L입니다.

ImmuPharma이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 ImmuPharma은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 ImmuPharma은(는) 0 GBP의 배당금을 지급할 것으로 예상됩니다.

ImmuPharma의 배당 수익률은 얼마입니까?

ImmuPharma의 현재 배당 수익률은 입니다.

ImmuPharma의 배당금은 언제 지급되나요?

ImmuPharma은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

ImmuPharma의 배당금은 얼마나 안전한가요?

ImmuPharma은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

ImmuPharma의 배당금은 얼마입니까?

향후 12개월 동안 0 GBP의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

ImmuPharma이(가) 속해 있는 섹터는 어디인가요?

ImmuPharma은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von ImmuPharma kaufen, um die vorherige Dividende zu erhalten?

ImmuPharma의 마지막 배당금을 0 GBP만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

ImmuPharma의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

ImmuPharma의 2023년도 배당금은 얼마였습니까?

2023년에 ImmuPharma는 0 GBP를 배당금으로 지급했습니다.

ImmuPharma는 어떤 화폐로 배당금을 지급하나요?

ImmuPharma의 배당금은 GBP에 지급됩니다.

증권거래소	ImmuPharma 티커
뒤셀도르프	25I.DU
프랑크푸르트	25I.F
LONDON	IMM.L
LONDON STOCK EXCHANGE	IMM.L
뮌헨	25I.MU

ImmuPharma 티커	ImmuPharma FIGI
IMM:LN	BBG000C01SG5
IMM:EO	BBG000R5VWP6
IMM:XL	BBG000R5VZZ8
IMM:E1	BBG000R5W262
IMM:XT	BBG000R5W2Y1
IMM:XW	BBG000R5W388
IMMEUR:EO	BBG000R9K8Q2
IMMEUR:E1	BBG000R9KGQ4
IMMEUR:XT	BBG000R9KGY5
IMMEUR:XW	BBG000R9KH64
IMM:EU	BBG000RF65R9
25I:GR	BBG000SVS5S8
25I:GF	BBG000SVS651
25I:GS	BBG000SVS7D0
25I:GM	BBG000SVS7J4
25I:GB	BBG000SVS7P7
IMM:PZ	BBG000SWKL45
IMML:PO	BBG002JV3565
IMM:XV	BBG005917YL1
IMMEUR:XV	BBG0059190Z8
IMML:B3	BBG006T76S56
IMML:L3	BBG006TB4Z26
IMMEUR:EU	BBG008FJ46K4
IMM:XX	BBG00JN75LP8
IMMEUR:XX	BBG00JN76NX4
IMML:TQ	BBG00MJH1JS0
IMM:X2	BBG00Q6QX644
25I:GZ	BBG00TZNQNS8

한 눈에 저평가된 주식을 인식하세요

ImmuPharma 주식 주식과 주식 분석 ImmuPharma ariva, ImmuPharma onvista, ImmuPharma finanzen.net, ImmuPharma aktienfinder, ImmuPharma marketscreener, ImmuPharma marketwatch, ImmuPharma bloomberg, ImmuPharma handelsblatt, ImmuPharma wiwo, ImmuPharma forum

가격

가격

티커IMM.L

ISINGB0033711010

WKNA0BMC4

ImmuPharma 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

ImmuPharma 주가 이력

ImmuPharma 주식 매출, EBIT, 이익 GB0033711010 · A0BMC4

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

ImmuPharma 매출, 이익 및 EBIT 역사

ImmuPharma 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

ImmuPharma 주식 마진 GB0033711010 · A0BMC4

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

ImmuPharma 마진 역사

ImmuPharma 주식 매출, EBIT, 주당 순이익 GB0033711010 · A0BMC4

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

ImmuPharma 매출, 이익 및 EBIT 주당 역사

ImmuPharma 주식 및 주식 분석

한눈에 과소평가된 주식을 인식하세요.

ImmuPharma Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

ImmuPharma 역사적인 P/E, EBIT 및 P/S에 따른 평가

한눈에 과소평가된 주식을 인식하세요.

ImmuPharma 주식 수량 GB0033711010 · A0BMC4

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

한눈에 과소평가된 주식을 인식하세요.

ImmuPharma 수익 예상

ImmuPharma 수익 놀라움

ImmuPharma 주식 주주 구조

ImmuPharma 임원진 및 경영진

ImmuPharma 주식에 대한 자주 묻는 질문

What values and corporate philosophy does ImmuPharma represent?

In which countries and regions is ImmuPharma primarily present?

What significant milestones has the company ImmuPharma achieved?

What is the history and background of the company ImmuPharma?

ImmuPharma 주식
주식과 주식 분석 ImmuPharma ariva, ImmuPharma onvista, ImmuPharma finanzen.net, ImmuPharma aktienfinder, ImmuPharma marketscreener, ImmuPharma marketwatch, ImmuPharma bloomberg, ImmuPharma handelsblatt, ImmuPharma wiwo, ImmuPharma forum

티커
IMM.L

ISIN
GB0033711010

WKN
A0BMC4